XiaoMi-AI文件搜索系统
World File Search SystemLocally
消费者对循环经济的态度
3.1对可持续性一词的意识6 3.2理解可持续性6 3.3熟悉循环经济，温室气体排放和净零8 3.4我知道我需要做什么，以帮助北爱尔兰减少温室气体的责任减少温室气体的责任，减少更循环经济的责任，成为循环经济更加循环范围。 might have on the environment 17 3.9 Things that would encourage the adoption of a more sustainable lifestyle 17 3.10 Buying locally produced food from local businesses 19 3.11 Choosing locally grown fruit and vegetables 19 3.12 Selecting food that is in season 20 3.13 Reducing the amount of red meat eaten 21 3.14 Reducing dairy consumption 21 3.15 Switching to dairy substitutes 22 3.16 Switching to meat substitutes 23 3.17 Eating a vegetarian饮食23 3.18吃素食饮食24 3.19最有可能有助于减少环境影响的事情25
室内机器人：Aehton模型规格Tug T2.5/T3/...
– Manufacturer: Aethon, USA – Assembly: TUG robots – Drive system: omnidirectional four-wheel drive – Navigation and sensor system: real-time multi-LiDAR, sonar and infrared sensors – Communication: WiFi or 900MHz – Area of application: indoor – Pick-ups and drop-offs: yes – Support: locally hosted or remote connection to the Aethon Command Center via a secure and encrypted VPN
肝胆临床试验PI CRC协议编号和标题...
Dose Escalation Phase: Histologically/cytologically-proven locally advanced or metastatic solid tumors for which no standard therapy exists or standard therapy has failed • HER2 expression by IHC and/or erbb2 amplification and/or erbb2-activating mutations Dose Expansion Phase: • UBC Cohort: must have received only 1L platinum-containing regimen for inoperable locally advanced/metastatic最后剂量•MBC队列后6个月，尿路上皮癌：转移性疾病的细胞毒性疗法不超过3种先前的细胞毒性疗法•Basket（HER2 3+）同伴：活检中的HER2 3+ <6个月•胃和食管队列：仅接受了1L中的胃和食管。不包括MSI-H。如果HER2在6个月内必须在抗PDL1下进行•NSCLC队列：必须在白金治疗后6个月内在铂duunum Doublet上进行进展，或者在W/中进展。如果HER2低于6个月内的抗PDL1，则必须在抗PDL1下进行。
Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis
*“内脏”（是/否）是指肺，肝，脑，胸膜和腹膜的参与； †可评估的仅骨疾病的患者不符合资格；疾病的患者仅限于骨骼，但具有裂解或混合裂解/肿瘤病变，并且每个恢复1.1的至少一个可测量的软组织组件可能符合条件。‡定义为每个ASCO-CAP指南10％。**根据第四eso – [ESMO]国际晚期乳腺癌的共识指南定义了内分泌耐药性。主要抵抗力：复发，而在辅助内分泌疗法的前两年。次要抵抗：至少2年后进行辅助内分泌治疗时复发或完成辅助内分泌疗法后的12个月内复发。ECOG PS，东方合作肿瘤学组绩效状况； ER，雌激素受体，Fulv，fulvestrant; Inavo，inavolisib; Palbo，Palbociclib； PBO，安慰剂； PGR，孕酮受体；恢复，实体瘤的反应评估标准。
o r i g i n a l r e s a r c h sintilimab与纳米颗粒结合的紫杉醇基于紫杉醇的化学疗法在严重的局部先进或metas
简介：鳞状非小细胞肺癌（SQNSCLC）与预后较差和有限的治疗选择有关。sintilizumab与化学疗法结合用作晚期SQNSCLC的一线治疗。然而，辛迪单抗与基于纳米颗粒的白蛋白结合的紫杉醇化疗相结合的严重鳞状NSCLC的化学疗法在临床研究中尚不清楚。方法：在2019年7月1日至12月31日之间，回顾性地收集了确认无法切除的III/IV期SQNSCLC的患者。根据表现状态（PS）得分，这些患者接受了一线Sintilimab加上基于NAB-PTX的化学疗法分为严重（PS = 2）和非严重性组（PS = 0-1）。每3周重复一次治疗方案，最多六个周期，或直到发生不可接受的毒性为止。这项研究的主要终点是评估无进展生存率（PFS），其继发终点在内，包括客观反应率（ORR），不良事件（AES）和疾病控制率（DCR）。结果：在367例无法切除的III/IV期SQNSCLC患者中，有28名男性患者中位年龄为65.5岁，接受了一线Sintilimab加上基于NAB-PTX的化学疗法。这些患者分为严重组（11例）和一个非严重性组（17例患者）。与非严重性组相比，严重组的慢性阻塞性肺疾病（COPD）的发生率明显更高（54.5％vs 11.8％，p = 0.03）。这两组的治疗周期和安全概况中位数中位数相似。尽管严重的组显示出比非严重性群体更高的ORR（63.6％vs 47.1％）和DCR（100％vs 76.5％），但这些差异在统计上并不显着。两组之间的PFS和Kaplan-Meier曲线的中间曲线也可比。结论：在一小部分严重的肺鳞状细胞癌群中，Sintilimab与基于NAB-PTX的化学疗法相结合的化疗是有效的，并且可以很好地耐受。这种组合可以为这些患者提供潜在的治疗选择。关键词：化学疗法，免疫疗法，严重的肺癌，鳞状非小细胞肺癌
大曼彻斯特快速运输策略草案（2024年7月）
Sustaining our rapid transit system: well-maintained, resilient and reliable ................................ 25 Integrating our rapid transit system: seamless and locally accountable ....................................... 26 Improving our rapid transit system: environmentally responsible and healthy ............................. 34 Improving our rapid transit system: safe, secure, accessible and inclusive ................................... 36 Growing our rapid transit system: longer vehicles, more车辆............................................... Transforming our rapid transit system: a second rapid transit hub around the Airport ................. 47 Transforming our rapid transit system: a step change in Regional Centre rapid transit capacity .. 48
KRAS G12D突变的实体瘤
• ≥18 years of age with locally advanced or metastatic solid tumor of any tissue origin with KRAS G12D mutation • Disease progression on prior standard treatment, intolerance of or ineligibility for standard treatment, or no available standard treatment to improve disease outcome • Parts 1a and 1d: histologically or cytologically confirmed malignant solid tumor of any tissue origin • Part 1b: diagnosis of PDAC, CRC, NSCLC,或其他晚期实体瘤，而不是先前疾病组的一部分•第1C部分：确认的PDAC，CRC或NSCLC•第2A部分和2B部分： - 西妥昔单抗组合：PDAC或CRC- retifanlimab-DLWR的诊断：PDAC，CRC，CRC，CRC，或NSCLC，或NSCLC
冰块电池存储
• Energy storage increases locally available power , may reduce grid load • Simultaneous charging and discharging of the battery storage system • Boost mode configuration for higher grid input to the battery • 150-1000Vdc output supports EV high voltage requirements • Dispenser and battery storage system can be physically separated by up to 300 feet • Access control via PIN or RFID card (cards by request) • Tempered glass touchscreen LCD display for durability and可读性•用于节省空间与脚印的紧凑型设计•OCPP 1.6标准支持互操作性•4＆5G LTE调制解调器和LAN连接到Incontrol•480V 3相输入，用于高效率转换
SGV优势
SGV & Co. • The leading and largest professional services firm in the Philippines • Offers integrated solutions drawn from diverse and deep competencies in assurance, tax, strategy and transactions, and consulting Respected Locally • Trusted by the most prestigious Filipino and international business organizations Recognized Globally • A member practice of Ernst & Young Global • Registered with the Public Company Accounting Oversight Board (USA) • The Assurance service line of SGV ＆Co。自1996年以来就一直获得ISO 9001认证，这是SGV的目的驱动公司，我们将培养领导者和使企业成为更好的菲律宾的目的是我们所做的一切的核心。此目的是我们成为“北极星”的理想理由 - 指导我们近6,000人通过当今迅速变化的世界。
Cadth报销建议
Evidence from one open-label phase III randomized controlled trial involving a total of 886 patients with locally advanced or metastatic urothelial cancer (Study EV-302) showed that treatment with enfortumab vedotin in combination with pembrolizumab demonstrated a clinically meaningful benefit compared to platinum plus gemcitabine chemotherapy (PLAT + GEM) in improving overall survival (HR: 0.468 [95% CI: 0.376，0.582]; p <0.00001），无进展生存率（HR = 0.450，95％CI：0.377，0.538; p <0.00001）和客观响应率（差异= 23.3％[95％CI，16.8％至29.6％]；Enfortumab Vedotin与Pembrolizumab结合使用的安全性与Enfortumab Vedotin单一疗法和pembrolizumab单一疗法的已知安全概况一致。